Next Phase Newsletter

The firm is an early-stage venture capital firm headquartered in Europe and currently investing from its second fund. The firm focuses on startups with proprietary technology and strong global growth potential across deeptech, future of work, fintech, healthtech, and digital health. The firm typically invests in Seed and Series A rounds, generally leading financings while also participating as a syndicate or co-investor when appropriate. Typical investment sizes range from approximately €700K to €1.5M. While the firm invests internationally, companies with connections to the Southeastern European region are viewed favorably.

The firm focuses on healthtech and digital health companies developing software-driven healthcare solutions. The firm is agnostic across healthcare subsectors and disease areas, provided the technology is primarily software-based and demonstrates meaningful innovation, scalability, and commercial potential.

From a company and management team perspective, the firm does not impose strict requirements but values founders with deep domain expertise, strong technological differentiation, and defensible intellectual property. Companies with ties to the Southeastern European ecosystem are considered a plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: AI, artificial-intelligence, business, entrepreneurship, finance, health, investing, technology

The firm is a private investment firm utilizing an asset-centric drug development model to advance early-stage biopharmaceutical programs. Rather than making traditional company-level investments, the firm primarily invests directly in individual therapeutic assets through flexible and innovative transaction structures. The firm can commit up to $25M or more per program, typically funding development through Phase II clinical proof-of-concept before pursuing value realization through licensing or acquisition by larger pharmaceutical companies. The firm invests globally and maintains a concentrated portfolio of high-potential therapeutic programs.

The firm focuses exclusively on biopharmaceutical assets, including small molecules, biologics, and advanced therapeutic modalities such as cell and gene therapies. The firm evaluates opportunities from approximately 12 to 18 months prior to IND through Phase I clinical development, with a preference for IND-ready, patent-protected programs addressing significant unmet medical needs and offering meaningful commercial potential. The firm is indication-agnostic and is open to a broad range of therapeutic areas where proof-of-concept can be established through early clinical studies.

From a company and management team perspective, the firm seeks founders with deep scientific and pharmacological expertise who are committed to a highly collaborative development model. The firm typically partners with lean, experienced teams and integrates each asset into a dedicated development structure while allowing founders to remain actively involved in program leadership. As a hands-on strategic partner, the firm provides extensive drug development expertise, operational resources, and industry relationships to efficiently advance programs through key value-inflection milestones.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: technology, health, AI, business, entrepreneurship, finance, investing, artificial-intelligence

The firm is a government-backed venture capital firm headquartered in Asia. The firm manages a large growth-stage investment fund while increasingly expanding its focus to earlier-stage innovation with global potential. Typical initial investments are approximately $5M, with the flexibility to deploy substantially larger amounts depending on the opportunity. Although the firm has historically invested primarily in domestic growth-stage companies, it is actively seeking early-stage opportunities globally.

The firm invests across therapeutics, digital therapeutics, medical devices, diagnostics, and digital health. Within therapeutics, the firm is modality-agnostic and evaluates opportunities across all disease areas. The firm generally prefers programs that have entered early clinical development and is less inclined to invest in preclinical-stage assets. Beyond therapeutics, the firm remains open to innovative healthcare technologies with strong commercial and global growth potential. From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition. The firm is open to acting as either a lead investor or co-investor and typically seeks board representation when serving as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: AI, artificial-intelligence, business, entrepreneurship, finance, health, investing, technology

The firm is the corporate venture capital arm of a global biopharmaceutical company and invests to support long-term strategic innovation alongside financial returns. The firm makes equity investments in emerging biotechnology companies, with typical initial investments ranging from approximately $1M to $6M and meaningful reserves for follow-on financings. The firm maintains a flexible investment pace and actively evaluates opportunities globally.

The firm focuses exclusively on biopharmaceutical companies developing therapeutics and therapeutic platform technologies, primarily at the preclinical stage. The firm is modality-agnostic and evaluates opportunities across small molecules, biologics, nucleic acid therapeutics, gene therapies, and cell therapies. Areas of strategic interest include immunology and autoimmune diseases, neuroscience with an emphasis on neurodegenerative disorders, and oncology. The firm does not invest in diagnostics, medical devices, or healthcare IT.

From a company and management team perspective, the firm seeks experienced leadership teams with strong domain expertise and scientific credibility. As a strategic investor, the firm typically prefers board representation and works closely with portfolio companies to support long-term development and strategic collaboration opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: AI, artificial-intelligence, business, entrepreneurship, finance, health, investing, technology

The firm is a life sciences accelerator, company creation platform, and investment organization founded in 2016 and based in the United States. As part of a broader healthcare investment ecosystem, the firm partners with scientists, entrepreneurs, and innovators to build and advance life sciences companies from early discovery through key clinical milestones. The firm provides capital, operational expertise, strategic guidance, and extensive industry relationships to accelerate the development of promising healthcare technologies. The firm typically makes Seed investments in the low single-digit millions and participates in larger Series A financings, while also syndicating opportunities alongside other investors. Through its broader investment network, portfolio companies may gain access to later-stage private, crossover, debt, and public market financing resources. The firm invests globally and supports companies from formation through clinical proof-of-concept and beyond.  

The firm invests broadly across life sciences and healthcare, including therapeutics, medical devices, diagnostics, and emerging healthcare technologies. The firm is modality-agnostic and evaluates a wide range of therapeutic approaches, including small molecules, biologics, peptides, antibodies, genetic medicines, cell therapies, and novel platform technologies. Beyond therapeutics, the firm is interested in diagnostics, medical technologies, digital health, telemedicine, artificial intelligence and machine learning-enabled healthcare solutions, and other enabling technologies that improve patient outcomes or healthcare delivery. The firm is generally disease-area agnostic and seeks innovative science addressing significant unmet medical needs.  

From a company and management team perspective, the firm is highly founder-friendly and open to working with a broad range of leadership teams, including first-time entrepreneurs and first-time CEOs. The firm takes a hands-on company-building approach, providing strategic, operational, scientific, and financing support throughout the company lifecycle. The firm typically prefers to lead investments and play an active role in company development while remaining open to syndicating opportunities alongside like-minded investors. The firm prioritizes strong science, differentiated technologies, and teams committed to building sustainable, high-impact healthcare companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: AI, artificial-intelligence, business, entrepreneurship, finance, health, investing, technology